Assessment of Interactions Between Intravenous Methamphetamine and Modafinil - 1
The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2005 by National Institute on Drug Abuse (NIDA).
Recruitment status was Active, not recruiting
Information provided by:
National Institute on Drug Abuse (NIDA)
First received: December 13, 2005
Last updated: October 25, 2007
Last verified: December 2005
The purpose of this study is to assess the potential interactions between intravenous methamphetamine and oral Modafinil.
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
||Double-Blind, Placebo-Controlled Assessment of Interactions Between Intravenous Methamphetamine and Modafinil
Primary Outcome Measures:
- Subjective symptoms/Mood Effects
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
The primary aims of this experiment are to determine if there are significant safety interactions between oral modafinil and intravenous methamphetamine. Safety will be assessed by measuring adverse events and cardiovascular responses of heart rate (HR), blood pressure (BP), and electrocardiogram (ECG) and stroke distance (ICG).
|Ages Eligible for Study:
||18 Years to 45 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- good physical and mental health
- body mass index between 18 and 30
- if female, using an acceptable method of contraception and are not pregnant
- able to give voluntary informed consent
- Please contact site for further details
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00265278
|U of CA, San Francisco
|San Francisco, California, United States, 94143 |
||Reese Jones, M.D.
||Langley Porter Psychiatric Institute
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||December 13, 2005
||October 25, 2007
||United States: Food and Drug Administration
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on May 26, 2015
Adrenergic Uptake Inhibitors
Central Nervous System Agents
Central Nervous System Stimulants
Dopamine Uptake Inhibitors
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Uptake Inhibitors
Peripheral Nervous System Agents
Physiological Effects of Drugs